Table 1.
Clinicopahtological characteristics of patients grouped according to GPS
| Variable | GPS 0 (n = 81) | GPS 1 (n = 49) | GPS 2 (n = 20) | P-value |
|---|---|---|---|---|
| Age (years) |
71 (43–91) |
74 (54–86) |
72 (51–79) |
0.05 |
| Sex (male/female) |
57/23 |
33/16 |
16/4 |
0.57 |
| HBsAg positive (%) |
8(10) |
4 (8.2) |
5 (25) |
0.12 |
| HCVAb positive (%) |
52 (65) |
24 (49) |
7 (35) |
0.03 |
| AST (IU/l) |
50 (18–148) |
58 (14–240) |
113 (13–384) |
<0.0001 |
| ALT (IU/l) |
39 (10–202) |
39 (12–190) |
78 (8–157) |
0.02 |
| Total serum bilirubin (mg/dl) |
0.7 (0.3-1.9) |
1 (0.3-6.1) |
1.6 (0.3-8.3) |
<0.0001 |
| Albumin (g/dl) |
3.9 (3.5-5) |
3.2 (2.1-4.6) |
3.2 (2.2-3.4) |
<0.0001 |
| CRP (mg/dl) |
0.1 (0.1-0.8) |
0.3 (0.1-2.9) |
2.6 (1.1-18.8) |
<0.0001 |
| WBC (cells/mm3) |
5300 (2500–14800) |
5100 (1800–14900) |
5800 (3900–12400) |
0.13 |
| Platelet count (104/mm3) |
14.2 (2.9-29.5) |
11.6 (1.8-42.1) |
17.3 (8.7-44.3) |
0.07 |
| Prothrombin time (%) |
85 (38–100) |
78 (41–100) |
77 (45–97) |
0.02 |
| α-fetoprotein (ng/ml) |
17 (1.9-59597) |
52 (2–138011) |
144 (1.7-280600) |
0.01 |
| Child-Pugh grade (A/B/C) |
78/2/0 |
22/25/2 |
6/10/4 |
<0.0001 |
| CLIP score (0/1/2/3≧) |
35/31/10/4 |
8/12/17/12 |
0/7/1/12 |
<0.0001 |
| JIS score (0/1/2/3≧) |
17/32/27/4 |
0/15/17/17 |
0/1/6/13 |
<0.0001 |
| BCLC score (0/A/B/C,D) |
16/41/19/4 |
1/24/14/10 |
0/6/2/12 |
<0.0001 |
| Tumor stage (І,ІІ,ІІІ,ІV) |
16/34/28/2 |
4/22/16/7 |
1/4/4/11 |
<0.0001 |
| Maximal tumor diameter (mm) |
28 (7–90) |
37 (10–200) |
50 (10–130) |
0 |
| Tumor number (solitary/multiple) |
45/35 |
26/23 |
5/15 |
0.04 |
| Vascular invasion (absent/present) |
77/3 |
44/5 |
13/7 |
0 |
| Extrahepatic metastasis (absent/present) | 79/1 | 47/2 | 17/3 | 0.02 |
Abbreviaions: HBsAg = hepatitis B surface antigen; HCVAb = hepatitis C antibody; AST = aspartate aminotransferase; ALT = alanine aminotransferase.
CRP = C-reactive protein; WBC = white blood cell count; ICG = indocyanine green dye retention rate at 15 minutes; CLIP = Cancer of the Liver Italian Program.
JIS = Japan Integrated Staging score; BCLC = Barcelona Clinic Liver Cancer; GPS = Glasgow Prognostic Score.